UGNE Insider Trading Activity and SEC Form 4 Filings
UGNE insider trading summary
No open-market insider purchases or sales of Unigene Laboratories Inc (UGNE) have been reported on SEC Form 4 in the past 12 months.
Latest UGNE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 21, 2011 | Thomas J Sabatino Jr | Director | Buy | $63K (100,000 @ $0.63) |
| Dec 21, 2011 | Paul Shields | Vice Pres. Mfg. Operations | Buy | $1K (2,000 @ $0.53) |
| Dec 21, 2011 | Nozer Mehta | VP, Biological R&D | Buy | $749 (1,400 @ $0.54) |
| Dec 21, 2011 | Theron Edwin Odlaug | Director | Buy | $5K (10,000 @ $0.53) |
| Dec 21, 2011 | Mayes, Gregory T. | VP, Corp Development and GC | Buy | $1K (2,000 @ $0.53) |
| Dec 21, 2011 | Ashleigh Palmer | President & CEO | Buy | $1K (2,500 @ $0.53) |
| Dec 21, 2011 | Ashleigh Palmer | President & CEO | Buy | $4K (7,500 @ $0.53) |
| Dec 21, 2011 | Jenene D. Thomas | VP of Investor Relations | Buy | $1K (2,000 @ $0.53) |
| Dec 21, 2011 | Joel A. Tune | Director | Buy | $8K (15,000 @ $0.56) |
| Dec 21, 2011 | Eiref Zvi | Director | Buy | $5K (10,000 @ $0.53) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.